This news item from Cornell Research is about: New anticancer agents are in great demand due to the heterogeneous nature of cancer and the development of resistance to existing drugs. This collaborative research with Robert Weiss, Biomedical Sciences, Richard Cerione, Molecular Medicine, and Hening Lin, Chemistry and Chemical Biology, aims to establish SIRT5 inhibition as new strategy to treat cancers.